Shots:
- Trial assessed Lilly’s retatrutide (9 & 12mg) + lifestyle intervention in adults with obesity or overweight & knee osteoarthritis, & without diabetes, meeting its co-1EPs with 26.4% (9mg) & 28.7% (12mg) vs 2.1% weight loss & reduced WOMAC pain by 4.5 & 4.4 vs 2.4 points
- It also reduced known CV risk markers & lowered systolic BP by 14 mmHg, with 14.1% & 12% experiencing pain-free knees vs 4.2%. In the treatment regimen estimand, it reduced weight by 20% & 23.7% (vs 4.6%), & improved WOMAC pain by 4 & 3.7 points (vs 2.1); an additional 7 readouts are planned for 2026, incl. 4mg maintenance dose results
- 2EPs showed 47.7% & 58.6% (vs 1.3%) achieving ≥25% loss, 30.5% & 39.4% (vs 0.8%) achieving ≥30%, 18.2% & 23.7% (vs 0%) achieving ≥35%, with physical function improved by 4.1 & 4.2 vs 2.1 points & ≥70% pain reduction in 73% & 67.7% vs 26.2%
Ref: Eli Lilly | Image: Eli Lilly | Press Release
Related News: Eli Lilly Reports P-III (BRUIN CLL-313) Trial Data on Jaypirca for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
